CohBar, Inc. (CWBR): Price and Financial Metrics
GET POWR RATINGS... FREE!
CWBR Stock Price Chart Interactive Chart >
CWBR Price/Volume Stats
|Current price||$0.20||52-week high||$2.27|
|Prev. close||$0.19||52-week low||$0.17|
|Day high||$0.20||Avg. volume||542,208|
|50-day MA||$0.25||Dividend yield||N/A|
|200-day MA||$0.55||Market Cap||17.09M|
CohBar, Inc. (CWBR) Company Bio
CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat Alzheimer's disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat Alzheimer's disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.
Most Popular Stories View All
CWBR Latest News Stream
|Loading, please wait...|
CWBR Latest Social Stream
View Full CWBR Social Stream
Latest CWBR News From Around the Web
Below are the latest news stories about CohBar Inc that investors may wish to consider to help them evaluate CWBR as an investment opportunity.
Good morning, trader!
Investment company Tri-Star Advisors Inc. (Current Portfolio) buys iShares TIPS Bond ETF, iShares Fallen Angels USD Bond ETF, BTC iShares MSCI USA Min Vol Factor ETF, BTC iShares Core MSCI EAFE ETF, iShares Agency Bond ETF, sells iShares 1-3 Year Credit Bond ETF, iShares Global Financials ETF, iShares Global Tech ETF, Vanguard S&P 500 ETF, Realty Income Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tri-Star Advisors Inc..
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference, being held virtually January 10 - 14, 2022. H.C. Wainwright
Penny stocks under $3 are full of potential and potential pitfalls.
Equities analysts expect CohBar, Inc. (NASDAQ:CWBR) to announce ($0.04) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for CohBars earnings. CohBar reported earnings per share of ($0.08) in the same quarter last year, which suggests a positive year-over-year growth rate of 50%. The company is 
CWBR Price Returns